Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC

Inclusion Criteria: * Male or female * Age ≥ 18 years，≤ 75 years * Patients with untreated resectable locally advanced biliary tract cancer (BTC) who are difficult to directly resecte surgically * Ability to provide written informed consent prior to participation in any study-related procedure * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * At least one, not previously irradiated, measurable lesion according to RECIST (version 1.1). * Adequate organ function Exclusion Criteria: * Diagnosis of mixed ampullary, hepatocellular, and cholangiocarcinoma * Known history of a serious allergy to any monoclonal antibody * Any active malignancy prior to the start of treatment * Active or history of autoimmune disease * Other acute or chronic conditions, psychiatric disorders, or laboratory abnormalities that may increase the risk of study participation * Pregnant or lactating women